Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ESMO prostate guideline recommends BRCA1, BRCA2, CDK12, and PALB2 testing in CRPC

The ESMO clinical practice guideline on advanced and metastatic prostate cancer, approved by the ESMO Guidelines Committee in January 2026, recommends genomic testing for BRCA1, BRCA2, CDK12, and PALB2 in all patients with castration-resistant prostate cancer, ideally before the first treatment for metastatic CRPC.

Annals of Oncology